No Data
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking -- Market Talk
Mizuho Securities Maintains In8bio(INAB.US) With Buy Rating, Maintains Target Price $8
Mizuho Securities analyst Uy Ear maintains $In8bio(INAB.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 37.7% and a total ave
Gold Gains 1%; US Consumer Sentiment Falls In June
IN8bio Is Maintained at Buy by Jones Trading
No Data